Association of S100B 3'UTR polymorphism with risk of chronic heart failure in a Chinese Han population

Abstract

To study the correlation between single nucleotide polymorphism (SNP) of the 3' untranslated region (UTR) rs9722 locus in S100B and the risk of chronic heart failure (CHF), plasma levels of S100B protein as well as has-miR-340-3p in a Chinese Han population.A total of 215 patients with CHF (124 ischemic cardiomyopathy (ICM) and 91 dilated cardiomyopathy (DCM)) and 215 healthy controls were recruited to analyze the S100B rs9722 genotype by Sanger sequencing. The levels of hsa-miR-340-3p in the plasma were detected by RT-PCR, and S100B levels were detected by ELISA.The risk of CHF in S100B rs9722 locus T allele carriers was 4.24 times higher than that in those with the C allele (95% CI: 2.84-6.33, P < .001). The association of S100B rs9722 locus SNP with ICM and DCM risk was not affected by factors such as age, gender, and body mass index (BMI). The levels of plasma S100B and hsa-miR-340-3p in patients with ICM and DCM were significantly higher than those in the control group (P < .001). There was no significant difference in plasma S100B levels between patients with ICM and DCM (P > .05). Among ICM, DCM, and control subjects, TT genotype carriers had the highest levels of plasma S100B and hsa-miR-340-3p, followed by the CT genotype and TT genotype, and the difference was statistically significant (P < .05). Plasma hsa-miR-340-3p levels were positively correlated with S100B levels in the control subjects and patients with ICM and DCM.The S100B rs9722 locus SNP is associated with CHF risk in a Chinese Han population.

Figure 1

Comparison of plasma S100B levels in ICM, DCM, and control groups. ns = no significant; ^∗∗∗P < .0001.

Figure 2

Plasma S100B levels in subjects with different genotypes of the S100B rs9722 locus. (A) Comparison of plasma S100B levels in different S100B rs9722 genotypes of patients with ICM. (B) Comparison of plasma S100B levels in different S100B rs9722 genotypes of patients with DCM. (C) Comparison of plasma S100B levels in different S100B rs9722 genotypes of healthy controls. ^∗∗P < .001; ^∗∗∗P < .0001.

Figure 3

Comparison of plasma hsa-miR-340-3p levels in ICM, DCM, and control groups. ns = no significant; ^∗∗∗P < .0001.

Figure 4

Plasma hsa-miR-340-3p levels in subjects with different genotypes at the S100B rs9722 locus. (A) Comparison of plasma hsa-miR-340-3p levels in different S100B rs9722 genotypes of patients with ICM. (B) Comparison of plasma hsa-miR-340-3p levels in different S100B rs9722 genotypes of patients with DCM. (C) Comparison of plasma hsa-miR-340-3p levels in different S100B rs9722 genotypes of controls. ^∗∗∗∗P < .00001.

Figure 5

Correlation between plasma hsa-miR-340-3p levels and S100B levels. (A) The level of plasma hsa-miR-340-3p was correlated with the level of plasma S100B in control subjects. (B) The level of plasma hsa-miR-340-3p was correlated with the level of plasma S100B in patients with ICM. (C) The level of plasma hsa-miR-340-3p was correlated with the level of plasma S100B in patients with DCM.